 <h1>Pexidartinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pexidartinib: oral capsule</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Capsule)</p><p>Pexidartinib can cause serious and potentially fatal liver injury. Monitor liver tests prior to initiation of pexidartinib and at specified intervals during treatment. Withhold dose and reduce or permanently discontinue pexidartinib based on severity of hepatotoxicity. Pexidartinib is available only through a restricted program call the Turalio Risk Evaluation and Mitigation Strategy (REMS) Program</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pexidartinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking pexidartinib:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>decreased appetite</li>
<li>dizziness</li>
<li>fever</li>
<li>headache</li>
<li>itching or skin rash</li>
<li>loss of appetite</li>
<li>nausea and vomiting</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
<li>swelling of the feet or lower legs</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Clay colored stools</li>
<li>confusion</li>
<li>dark urine</li>
<li>defects in intelligence, short-term memory, learning ability, and attention</li>
<li>stomach pain or tenderness</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pexidartinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning, tingling, numbness or pain in the hands, arms, feet, or legs</li>
<li>change or loss of taste</li>
<li>difficulty having a bowel movement (stool)</li>
<li>hair color changes</li>
<li>sensation of pins and needles</li>
<li>stabbing pain</li>
<li>swelling of the eyes</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Change in color vision</li>
<li>changes in skin coloring</li>
<li>darkening or lightening of skin color</li>
<li>decrease in vision</li>
<li>difficulty seeing at night</li>
<li>double vision, seeing double</li>
<li>dry mouth</li>
<li>hair loss, thinning of hair</li>
<li>increased sensitivity of the eyes to sunlight</li>
<li>irritation, soreness, or swelling of the mouth</li>
</ul><p>
<!-- end oral capsule --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pexidartinib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): decreased neutrophils (44%), decreased lymphocytes (38%), de creased hemoglobin (30%), decreased platelets (15%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Eye edema (30%)</p>
<p><b>Common</b> (1% to 10%): Blurred vision, photophobia, diplopia, reduced visual acuity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased lactate dehydrogenase (92%), increased cholesterol (44%), decreased phosphate (25%), anorexia (16%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (61%), increased ALT (31%), increased ALP (31%) </p>
<p><b>Common</b> (1% to 10%): Increased bilirubin, cholangitis, hepatotoxicity, liver disorder<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (64%), peripheral edema (20%)</p>
<p><b>Common</b> (1% to 10%): Pyrexia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia/ageusia (26%), neuropathy (e.g., neuropathy peripheral, paresthesia, hypoesthesia, burning sensation) (10%)</p>
<p><b>Common</b> (1% to 10%): Cognitive disorders (memory impairment, amnesia, confusional state, disturbance in attention, attention deficit/hyperactivity disorder)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (15%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hair color changes (67%), rash (e.g., maculopapular rash, rash pruritic, urticaria, erythema, dermatitis acneiform, dermatitis allergic) (28%), pruritus (18%)</p>
<p><b>Common</b> (1% to 10%): Alopecia, skin pigment changes (hypopigmentation,</p>
<p>depigmentation, discoloration, hyperpigmentation)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (20%), constipation (12%)</p>
<p><b>Common</b> (1% to 10%): Dry mouth, stomatitis, mouth ulceration<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about pexidartinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pexidartinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Turalio</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Tenosynovial Giant Cell Tumor</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pexidartinib: oral capsule</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): decreased neutrophils (44%), decreased lymphocytes (38%), de creased hemoglobin (30%), decreased platelets (15%)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Eye edema (30%)</p><p><b>Common</b> (1% to 10%): Blurred vision, photophobia, diplopia, reduced visual acuity<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Increased lactate dehydrogenase (92%), increased cholesterol (44%), decreased phosphate (25%), anorexia (16%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased AST (61%), increased ALT (31%), increased ALP (31%) </p><p><b>Common</b> (1% to 10%): Increased bilirubin, cholangitis, hepatotoxicity, liver disorder<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (64%), peripheral edema (20%)</p><p><b>Common</b> (1% to 10%): Pyrexia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Dysgeusia/ageusia (26%), neuropathy (e.g., neuropathy peripheral, paresthesia, hypoesthesia, burning sensation) (10%)</p><p><b>Common</b> (1% to 10%): Cognitive disorders (memory impairment, amnesia, confusional state, disturbance in attention, attention deficit/hyperactivity disorder)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (15%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Hair color changes (67%), rash (e.g., maculopapular rash, rash pruritic, urticaria, erythema, dermatitis acneiform, dermatitis allergic) (28%), pruritus (18%)</p><p><b>Common</b> (1% to 10%): Alopecia, skin pigment changes (hypopigmentation,</p><p>depigmentation, discoloration, hyperpigmentation)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (20%), constipation (12%)</p><p><b>Common</b> (1% to 10%): Dry mouth, stomatitis, mouth ulceration<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ. </p><h2>More about pexidartinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Pexidartinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Tenosynovial Giant Cell Tumor</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>